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Abstract
Autophagy plays a role in deciding the fate of cells by inducing either survival or death. 1’S-
1-acetoxychavicol acetate (ACA) is a phenylpropanoid isolated from rhizomes of Alpinia
conchigera and has been reported previously on its apoptotic effects on various cancers.
However, the effect of ACA on autophagy remains ambiguous. The aims of this study were
to investigate the autophagy-inducing ability of ACA in human non-small cell lung cancer
(NSCLC), and to determine its role as pro-survival or pro-death mechanism. Cell viability
assay was conducted using MTT. The effect of autophagy was assessed by acridine orange
staining, GFP-LC3 punctate formation assay, and protein level were analysed using western
blot. Annexin V-FITC/PI staining was performed to detect percentage of cells undergoing
apoptosis by using flow cytometry. ACA inhibits the cell viability and induced formation of
cytoplasmic vacuoles in NSCLC cells. Acidic vesicular organelles and GFP-LC3 punctate
formation were increased in response to ACA exposure in A549 and SK-LU-1 cell lines;
implying occurrence of autophagy. In western blot, accumulation of LC3-II accompanied by
degradation of p62 was observed, which further confirmed the full flux of autophagy induc-
tion by ACA. The reduction of Beclin-1 upon ACA treatment indicated the Beclin-1-indepen-
dent autophagy pathway. An early autophagy inhibitor, 3-methyaldenine (3-MA), failed to
suppress the autophagy triggered by ACA; validating the existence of Beclin-1-independent
autophagy. Silencing of LC3-II using short interfering RNA (siRNA) abolished the autophagy
effects, enhancing the cytotoxicity of ACA through apoptosis. This proposed ACA triggered
a pro-survival autophagy in NSCLC cells. Consistently, co-treatment with lysosomal inhibi-
tor, chloroquine (CQ), exerted a synergistic effect resulting in apoptosis. Our findings sug-
gested ACA induced pro-survival autophagy through Beclin-1-independent pathway in
NSCLC. Hence, targeting autophagy pathway using autophagy inhibitor such as CQ
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represented a novel promising approach to potentiate the cytotoxicity of ACA through apo-
ptosis in NSCLC.
Introduction
Lung cancer is the most common cancer worldwide; accounting for 1.82 million new cases
and 1.6 million deaths in 2012 [1]. Among the lung cancer cases, non-small cell lung cancer
(NSCLC) contributes to approximately 85% and has a low 5-year survival rate [2]. Conven-
tional cancer therapies such as surgery, chemotherapy and radiotherapy were found to have
limitation in maintaining its effectiveness during the course of therapy which lead to recur-
rence and acquired apoptosis resistance in long term treatment [3]. Hence, it is crucial to eluci-
date the underlying reason to improve the efficiency of the available therapeutic agents.
Emerging evidences proposed that identifying the role played by autophagy in cancer could be
a strategy to overcome resistance towards chemotherapy due to the fact its potential in eliciting
a pro-survival or pro-death effect in response to metabolic and therapeutic stresses [4, 5].
Autophagy is a self-eating mechanism that is highly regulated by a set of autophagy-related
(atg) genes to maintain the homeostasis in the cells through recycling of cellular components
upon lysosomal degradation [6, 7]. Unlike canonical autophagy, a non-canonical autophagy
occurs when certain ATG proteins such as ULK1, Beclin-1, class III phosphotidylinositol-
3-kinase (PI3K) and Atg conjugation system are being bypassed during initiation of autophagy
and formation of autophagosome [6, 7]. It was believed that autophagy induction often occur
prior apoptosis to provide energy to allow survival of cancerous cells in response to stress such
as nutrient deprivation or chemotherapy stress [8, 9]. Conversely, natural bioactive com-
pounds such as silvestrol and guttiferon K were proven to elicit autophagy that lead to cell
death [10, 11]. To date, the role of autophagy in cancer remains ambiguous due to the complex
cross-talk machinery with apoptosis. Understanding of this mechanism is crucial in develop-
ing effective cancer therapy as it is a key regulator in determining the cell fate.
Natural products have attracted the attention of researchers due to their anti-cancer prop-
erty. 1’S-1-acetoxychavicol acetate (ACA) is a phenylpropanoid isolated from rhizomes of
Alpinia conchigera Griff. Our group had previously reported the anti-cancer effects of ACA in
breast (MCF-7), oral (HSC-2 and HSC-4), liver (HepG2), cervical (CaSki), lung cancer (A549)
and prostate carcinoma (PC-3) via inducing apoptosis with minimal cytotoxic effect on nor-
mal human mammary cells (HMEC) and no physiological alteration in in vivo model [12–14].
It was reported that ACA targets NF-κB signalling pathway to alter the pro-inflammatory
microenvironment environment both in vitro and in vivo [12, 14]. Despite numerous reports
on its direct interaction on signalling pathway, ACA can modulate epigenetic machinery in
cancer by altering miRNA expression that eventually has an impact in the gene expression
[15]. Moreover, a synergistic anti-cancer effect was further observed in combination treatment
of ACA with cisplastin or recombinant human alpha fetoprotein [12, 14, 15]. These studies
revealed ACA as a potential anti-cancer remedy. Although it was known that ACA induced
cytotoxicity against wide range of cancer types, its effect on autophagy remains ambiguous.
The aims of this study were to investigate the autophagy-inducing ability of ACA in human
NSCLC. Effect of ACA on cytotoxicity and apoptosis induced was assessed after administering
autophagy inhibitors and small interfering RNA (siRNA). Role of ACA-induced autophagy as
pro-survival or pro-death mechanism was determined. In present study, we have shown that
ACA triggered autophagy through non-canonical pathway in NSCLC and autophagy
Inhibition of autophagy enhanced apoptotic effect of ACA in lung cancer
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inhibitors can potentiate the cytotoxicity of ACA through apoptosis. Our results suggested
autophagy inhibitors as a potential strategy to improve the efficiency of the ACA in future.
Materials and methods
Plant material
Rhizomes of wild Alpinia conchigera Griff were collected from Jeli (5˚420N 101˚500E) province
of Kelantan, east-coast of Penisular Malaysia. No specific permission was required for collecting
the sample from this site as they are wildly grown and thi field study did not involve endangered
or protected species. The sample was identified by Prof. Dr. Halijah Ibrahim from Institute of
Biological Science, University of Malaya. A voucher specimen (KL5049) was deposited in Her-
barium of Chemistry Department, Faculty of Sciece, University of Malaya.
Chemicals and antibodies
ACA was dissolved in dimethyl sulfoxide (DMSO; Fisher Scientific, USA) to serve as a stock
solution. The autophagy inhibitors used were 3-methyladenine (3-MA; Calbiochem, USA)
and chloroquine diphosphate (CQ; Sigma, USA). The 3-MA was dissolved directly in culture
media and the stock solution CQ was prepared in distilled water. Acridine orange solution was
obtained from Sigma. Roswell Park Memorial Institute-1640 (RPMI-1640) medium was pur-
chased from GE Healthcare HyClone (USA) whereas alpha-Minimum Essential Medium (α-
MEM) was obtained from Nacalai Tesque (Japan). Fetal bovine serum (FBS) was from Sigma
(USA).
Primary antibodies included rabbit antibodies against microtubule associated protein 1
light chain 3-I/II (LC3-I/II), p62, GAPDH and mouse antibodies against Beclin-1 were used.
Anti-rabbit IgG and anti-mouse IgG horseradish peroxidase (HRP)-conjugated secondary
antibody were used. All the antibodies were purchased from Cell Signaling Technology (USA).
Cell culture
Two human NSCLC cells lines A549 was purchased from America Type Culture Collection
(ATCC, USA) and SK-LU-1 was purchased from AseaCycte Sdn. Bhd., Malaysia. A549 cells
were cultured in RPMI-1640 medium while SK-LU-1 cells were cultured in α-MEM medium.
The media were supplemented with 10% (v/v) FBS and cells maintained at 37˚C incubator
with 5% CO2. A non-tumourigenic human mammary epithelial cells, MCF 10A was purchased
from ATCC and cultured in Mammary Epithelial Cell Growth Medium (MEGM) supple-
mented with 100 ng/ml cholera toxin.
MTT cell viability assay
Briefly, cells were seeded at a density of 1×104 cells/well in 96-well plate and treated with ACA
(0–30 μM) for 24 h. Following incubation, MTT (5 mg/ml) (Merck, Germany) with a volume
of 10 μl was added to each well and the cells were incubated at 37˚C incubator for 1 h. The for-
mazan crystal was dissolved in 200 μl of DMSO. The absorbance reading at 560 nm with back-
ground subtraction at 630 nm was measured by Tecan Sunrise microtitre plate reader using
Magellan Software Version 6.3. The IC50 of ACA for each of the cell lines was then determined
and this IC50 was used for the downstream experiments in this study. MCF 10A was used to
determine the toxicity of ACA on non-tumourigenic cells. To investigate the time-dependent
effect, the cell viability of A549 and SK-LU-1 cells at IC50 value was assessed from 0–24 h. To
evaluate the effect of autophagy on ACA-induced cell death, the cells were pre-treated with
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siLC3 (20 nM) or CQ (20 μM) for 4 h, followed by addition of IC50 concentration of ACA for
24 h and the cell viability was measured.
Morphological observation
Cells were seeded and treated with ACA, 3-MA, CQ standalone or in combination of ACA
with inhibitors. At 24 h, the morphology of cells was examined under a bright field Nikon
Eclipse TS100 inverted fluorescent microscope (Nikon, Japan) at 200 × magnification.
Acidic Vesicular Organelles (AVO) staining
Cells were plated in 6-well plate and incubated overnight at 37˚C incubator with 5% CO2 for
adherence. The following day, cells were incubated with ACA for 0, 3, 6, 12 and 24 h or in pres-
ence of siLC3 or CQ for 24 h. At indicated time point, cells incubated with acridine orange
(AO) (1μg/ml) (Sigma-Aldrich, USA) at 37˚C for 15 minutes. The cells were observed under
Nikon Eclipse TS100 inverted fluorescent microscope (Nikon, Japan) using a blue filter (B-2A)
at 400 × magnification. The red relative fluorescence intensity (RFI) which represent the AVO
was measured using Nikon NIS-BR Element software.
Analysis of GFP-LC3-II
Cells were seeded at in 6-well plate and incubate overnight in 37˚C incubator with 5% CO2 for
attachment. All cells were transduced with RFP-GFP-LC3-II reagent using commercially avail-
able Premo Autophagy Tandem Sensor RFP-GFP-LC3-II Kit (Life technologies, USA) and
treated with ACA for 0, 3 and 6 h or in presence of siLC3 or CQ for 6 h. At indicated time
point, the cells were visualized under Nikon Eclipse TS100 inverted fluorescent microscope
(Nikon, Japan) using a blue filter at 400 × magnification to detect the neutral pH autophago-
some with GFP emission. Cells with five GFP-LC3-II dots were regarded as positive cells.
Quantitation of GFP-LC3-II was examined by counting the number of cells with positive
punctate dots in a total of 200 GFP-LC3-II cells.
Western blot analysis
Cellular proteins were extracted using NE-PER1 Nuclear & Cytoplasmic Extraction Kit
(Pierce, USA) according to manufacturer’s protocol. The lysate proteins were quantitated
using bicinchoninic acid (BCA) protein assay kit (Thermo, USA) according to manufacturer’s
instruction. For western blot analysis, 20 μg of lysate proteins were resolved using 12% sodium
dodecyl sulphate-polyacrylamide gels (SDS-PAGE) and transferred to a nitrocellulose mem-
brane. The membrane was incubated in relevant primary antibody overnight at 4˚C at appro-
priate dilution. Anti-GAPDH antibody was used at a 1:10000 dilution whereas anti-LC3-I/II,
anti-p62, and anti-Beclin-1 were used at a 1:1000 dilution. On the following day, membranes
were incubated with anti-biotin and HRP-conjugated secondary antibody at a 1:1:1000 dilu-
tion at room temperature with agitation. Detection of bound antibody was done by subjecting
the membrane to 1: 1 of Western Bright Quantum components (Advansta, USA) for 2 min in
the dark. Protein bands were visualized using a chemiluminescent imaging system (Fusion
FX7). GAPDH was used for normalization of band intensity by using ImageJ v1.48 (NIH,
USA) densitometry software.
RNA interference
The cells were seeded 24 h before transfection. Small interfering RNA (siRNA) against LC3
(siLC3) (Origene, USA) or universal scrambled negative control siRNA (OriGene, USA) were
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transfected at a concentration of 20 nM using Dharmfect I tranfection reagent (Dharmacon,
USA) according to the manufacturer’s manual. The knockdown efficiency of 3 unique siRNA
duplexes was examined using western blot analysis and the one with best knockdown effi-
ciency was selected for the subsequent experiments. Sequence of the 3 unique siRNA duplexes
is shown in Table 1.
Annexin V-FITC/PI apoptosis assay
Apoptosis was measured by annexin V-FITC apoptosis detection kit (Calbiochem, USA)
according to the manufacturer’s instruction. Briefly, the seeded cells were pre-treated with
siLC3 (20 nM) or CQ (20 μM) (Sigma-Aldrich, USA) for 4 h, followed by addition of IC50 con-
centration of ACA for 24 h. At indicated time point, both floating and attached cells were har-
vested, washed with cold PBS, and followed by incubation with 500 μl binding buffer
containing 1.25 μl of annexin V-FITC and 10 μl of propidium iodide (PI) in the dark. The sam-
ples were analysed using BD FACSCantoII flow cytometer (BD Biosciences, USA) with BD
FACSDiva (BD Biosciences, USA) software.
Statistical analysis
The data are presented as mean ± standard deviation (SD) of at least three independent experi-
ments. The statistical data analysis was performed using one-way ANOVA, followed by post-
hoc Turkey analysis, with a p value of< 0.05 indicating a statistically significant difference.
Results
ACA inhibited the cell viability in NSCLC cell lines
We have previously characterized the structure of ACA (Fig 1A) and reported on its cytotoxicity
towards various cancer cell lines [13]. In current study, the cytotoxic effect of ACA treatment in
NSCLC cell lines (A549 and SK-LU-1) was investigated by exposing the cells to increasing doses
of ACA (0–30 μM) for 24 h. Results indicated ACA elicited a dose-dependent cytotoxicity in
both A549 and SK-LU-1 cell lines. The IC50 value of ACA in A549 and SK-LU-1 cells were
29.2 ± 1.4 μM and 25.0 ± 1.0 μM respectively. This implied ACA is slightly more sensitive
towards SK-LU-1 in comparison to A549 cell lines (Fig 1B). Based on the results from MTT
assay, the IC50 values of respective cell lines at 24 h were used for subsequent experiments. On
the other hand, the cell viability of MCF 10A maintains above 75% after treated with ACA at
30 μM for 24 h with undetermined IC50. We also conducted a time-dependent study (0–24 h) of
ACA at IC50 value in A549 and SK-LU-1 cell line. In Fig 1C, the cell viability of A549 declined
more rapidly in comparison to SK-LU-1 at their respective IC50 value for ACA (Fig 1C). Under
microscopic examination, ACA induced morphological changes in cells as compared to the
untreated group with increased cytoplasmic vacuoles in both NSCLC cell lines (Fig 1D); sug-
gesting the possibility of autophagy induction.
Table 1. Sequence of three unique 27 mer siRNA duplexes targeting LC3 (OriGene, USA).
siRNA Duplex sequence
A 5’-CCUGUAUACGUUAGUGAAAGCUGTT-3’
B 5’-UACAGAUACUAAUGUCAAGAGUUAA-3’
C 5’-CGUUUAGACUGUAUACAUCAUAUCT-3’
doi:10.1371/journal.pone.0171329.t001
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ACA induced autophagy in NSCLC cells
To investigate the induction of autophagy, AO staining was used to detect the presence of
acidic vesicular organelles (AVO). AO stain will emit red fluorescence in acidic vesicles organ-
elles whereas green fluorescence in non-acidic compartment such as cytoplasm and nucleus
[16]. After ACA treatment, both AO stained A549 and SK-LU-1 cells exhibited a significant
increase in red fluorescence signal that indicated the presence of AVO in comparison to
untreated cells (Fig 2A and S1 Fig).
Autophagy activity of ACA was verified by localizing the LC3, a marker of autophagosome,
by observing the formation of GFP-LC3-II punctate in the cells. ACA exerted an accumulation
of GFP-LC3 punctate in comparison to the diffused pattern of green fluorescence seen in
untreated cells (Fig 2B and S1 Fig). Consistent with the results of GFP-LC3-II punctate forma-
tion analysis, elevated LC3-II protein expression in A549 and SK-LU-1 cell lines was observed
after ACA treatment (Fig 2C). The LC3-II protein expression upon ACA exposure peaked ear-
lier at 6 h in A549 cells compared to 12 h in SK-LU-1 cells. This may indicate that ACA pro-
motes the recruitment of LC3-II into autophagosomes earlier in A549 cells. In the untreated
SK-LU-1 cells, a basal level of GFP-LC3-II punctate was seen. However. this level was signifi-
cantly increased at 3 h (p< 0.05) and 6 h (p< 0.01) when treated with ACA.
Fig 1. ACA inhibited cell viability of A549 and SK-LU-1 cell lines. (A) Chemical structure of 1’S-1’-acetoxychavicol acetate (ACA). (B) The cell viability
of MCF 10A, A549 and SK-LU-1 cells lines after exposure to ACA (0–30 μM) for 24 h was assessed using MTT assay. Data represented as mean percentage
of cell viability ±SD for three independent experiments. (C) The cell viability of A549 and SK-LU-1 cells lines after exposure to IC50 of ACA (25 μM for SK-LU-
1 and 30 μM for A549 cells) on respective cell lines for 0–24 h was assessed using MTT assay. Data represented as mean percentage of cell viability ±SD for
three independent experiments. * p < 0.05 and ** p < 0.01 statistically different in comparison to 0 h (D) Representative photomicrograph (200 ×magnific-
ation) of A549 and SK-LU-1 cell lines upon ACA treatment. Arrow indicates the cytoplasmic vacuole.
doi:10.1371/journal.pone.0171329.g001
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Fig 2. Autophagy effect of ACA on A549 and SK-LU-1 cell lines. (A) Representative fluorescence photomicrograph (400 ×magnification)
illustrating the acidic vesicular organelles in A549 and SK-LU-1 cell lines after treated with ACA for 0, 3, 6, 12, and 24 h. Data were presented as
relative fluorescence intensity in comparison to untreated cells ± SD. * p < 0.05, ** p < 0.01, and *** p < 0.001 statistically different in comparison
to untreated. (B) Representative fluorescence photomicrograph (400 ×magnification) illustrating the GFP-LC3-II punctate formation in A549 and
SK-LU-1 cell lines upon exposure to ACA. Data were represented as mean percentage of cells with GFP-LC3-II punctate ± SD of three indepen-
dent experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 statistically different in comparison to untreated. (C) Protein expression of LC3-I/II
and p62 after ACA treatment in A549 and SK-LU-1 cell lines. Data were represented as mean normalized intensity ± SD of three independent
experiments. * p < 0.05, ** p < 0.01, and *** p < 0.001 statistically different in comparison to untreated.
doi:10.1371/journal.pone.0171329.g002
Inhibition of autophagy enhanced apoptotic effect of ACA in lung cancer
PLOS ONE | DOI:10.1371/journal.pone.0171329 February 3, 2017 7 / 17
In order to monitor the autophagy flux, we further assessed the degradation of p62 protein
expression. Impaired autophagy will lead to accumulation of p62; whereas reduction in expres-
sion of p62 indicates an effective autophagy flux [17]. In this study, we noted ACA down-regu-
lated the protein expression of p62 in A549 and SK-LU-1 cells in a time-dependent manner
(Fig 2C); indicating a functional autophagy machinery was activated by ACA in these cell
lines.
ACA-induced autophagy is independent of Beclin-1/PI3K complex in
NSCLC cell lines
Studies have shown initiation of autophagy can be Beclin-1-dependent (canonical) or Beclin-
1-independent (non-canonical) [7]. To examine the involvement of Beclin-1 in ACA-induced
autophagy, we first examined the expression of Beclin-1 protein level using western blot. Our
data demonstrated that ACA treatment reduced the expression of Beclin-1 in a time-depen-
dent manner in A549 and SK-LU-1 cells (Fig 3A). Reduction in Beclin-1 protein expression
was reported to be representative characteristic of a non-canonical autophagy pathway [18,
19]. Hence, we hypothesized ACA triggered autophagy bypasses the Beclin-1/PI3K complex.
In order to verify the non-involvement of Beclin-1/PI3K complex in ACA-induced autophagy,
we blocked the Beclin-1/PI3K complex in early process of autophagy using a PI3K class III
inhibitor, 3-methyladenine (3-MA). Previous studies showed that 3-MA with concentration of
5 mM can be used to inhibit the early autophagy in lung cancer cells [20, 21]. In these investi-
gations, 3-MA standalone does not show a decrease in basal autophagy and LC3-I expression.
Our current study demonstrated administration of 3-MA did not block the red relative fluo-
rescence intensity (RFI) of AO induced by ACA (Fig 3B and S2 Fig), indicating non-involve-
ment of Beclin-1/PI3K complex. Consistently, western blot and GFP-LC3-II revealed that pre-
treatment with 3-MA prior to ACA treatment failed to suppress LC3-II protein expression
(Fig 3C and 3D and S2 Fig). This further verified that ACA induced Beclin-1/PI3K-indepen-
dent autophagy. MTT assay was conducted using 3-MA standalone, ACA standalone and
combination of 3-MA with ACA to assess the effect of 3-MA on cell viability. The cell viability
was maintained at similar level, which is from 55.4 ± 7.9% to 54.7 ± 9.4% and from 50.8 ± 4.2%
to 47.0 ± 4.1% in A549 and SK-LU-1cell lines respectively with pre-treatment of 3-MA prior to
ACA treatment (Fig 3E). This indicated that 3-MA has no significant effect on cell viability of
A549 and SK-LU-1 cells; most probably attributed by the autophagy flux that could not be
inhibited using 3-MA.
Knockdown of LC3 enhanced ACA-induced cytotoxicity through
apoptosis
To clarify the role of ACA-induced Beclin-1/PI3K-independent autophagy in cell death, we
inhibited the process of autophagy in NSCLC cells by reducing LC3 expression, which is the
key player in forming autophagsome. First, the efficiency of the 3 unique siRNA duplexes tar-
geting LC3, siRNA3 A, B and C were assessed using western blot. siRNA A targeting LC was
selected for the downstream experiments due to its best knockdown ability in both A549 and
SK-LU-1 cells (Fig 4A). Result showed siRNA A inhibited the protein expression of LC3 suc-
cessfully in both NSCLC cell lines even when ACA was presented (Fig 4B). After transfected
with siLC3, the cell viability upon ACA exposure was decreased from 40.8 ± 6.9% to
20.8 ± 1.7% in A549 cells, while 51.0 ± 6.3% to 35.1 ± 1.3% in SK-LU-1 cells (Fig 4C). Adminis-
tration of ACA increased apoptosis in LC3 silenced NSCLC cells (Fig 4D). This implies that
the autophagy mediated by ACA limits the death inducing effect in these cells and was taking
on a pro-survival role.
Inhibition of autophagy enhanced apoptotic effect of ACA in lung cancer
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Autophagy inhibitor chloroquine enhanced ACA-induced cytotoxicity
through apoptosis
We further investigated the effect of the inhibitor, chloroquine (CQ) that inhibits lysosomal
turnover of autophagosome contents during the ACA-induced autophagy. Administration of
CQ (20 μM) alone blocked the fusion of autophagosome and lysosome; leading to accumula-
tion of LC3-II formation and lysosomes. The RFI of ACA in combination with CQ was
increased in NSCLC cells; indicating the increase in acidic compartments (Fig 5A and S3 Fig).
GFP-LC3-II punctate and western blot showed that CQ further elevated the LC3-II protein
level induced by ACA (Fig 5B and 5C and S3 Fig). These data confirmed that ACA stimulated
autophagy. In the MTT assay, cell viability was reduced significantly from 53.3 ± 1.0% to
46 ± 2.4% and 53.6 ± 2.9% to 45 ± 2.9% in A549 and SK-LU-1cell lines respectively with pre-
treatment of CQ prior to ACA treatment (Fig 5D). In addition, annexin V-FITC/PI staining
disclosed that pre-treatment with CQ increased ACA-induced apoptotic cells (Fig 5E). These
results proposed the pharmacological inhibition of autophagy using autophagy inhibitor such
as CQ can potentiate the cytotoxic ability of ACA to induce apoptosis; thus giving a new per-
spective for improvement of chemotherapeutic outcome in the future.
Discussion
The naturally occurring ginger compound, ACA, has been extensively studied which revealed
its potential as an anti-cancer agent through activation of apoptosis [12–14]. However, the
ability of ACA to induce autophagy in NSCLC remains unclear. Our current study revealed
that ACA induced autophagy in NSCLC as evidenced by the accumulation of AVO and
GFP-LC3-II along with elevated LC3-II protein level indicating the recruitment LC3-II on
autophagosomes. Furthermore, degradation of p62 observed further implied that ACA
induced autophagy flux. This is the first study reporting on autophagy inducing ability of ACA
in NSCLC. Natural occurring compounds such as curcumin and resveratrol were also found
to activate autophagy and/or apoptosis via reactive oxygen species (ROS) pathway in oral and
colon carcinoma respectively [22–24]. Previous studies reported that ACA can stimulate the
production of ROS in myeloid leukemia and hepatocellular carcinoma [25, 26]. This might be
the possible mechanism of ACA regulating autophagy in both A549 and SK-LU-1 cells.
Autophagy is governed by a series of ATG proteins for initiation and followed by formation of
autophagosome. One of the major components during formation of autophagosome in canonical
autophagy pathway is PI3K complex which consists of Beclin-1, Vps34 and UVRAG/Atg14. Sub-
stantial studies demonstrated activation of autophagy can be in a Beclin-1/PI3K-independent
manner. For instance, gossypol can initiate autophagy in the absence of Beclin-1 in HeLa cells
Fig 3. ACA-induced autophagy is independent of Beclin-1/PI3K complex in A549 and SK-LU-1 cell lines. (A) Protein expression of
Beclin-1 after ACA treatment in A549 and SK-LU-1 cell lines. Data were represented as mean normalized intensity against GAPDH ± SD. ***
p < 0.001 statistically different in comparison to untreated. (B) Representative fluorescence photomicrograph (400 ×magnification) illustrating
the acidic vesicular organelles in A549 and SK-LU-1 cell lines after treatment with ACA in presence or absence of 3-MA. Data were presented
as relative fluorescence intensity in comparison to untreated cells ± SD of three independent experiments * p < 0.05 and ** p < 0.01 statisti-
cally different in comparison to untreated. # p < 0.05 and ## p < 0.01 statistically different in comparison to 3-MA. (C) Representative fluore-
scence photomicrograph (400 ×magnification) illustrating the GFP-LC3-II punctate formation in A549 and SK-LU-1 cell lines upon exposure to
co-treatment of 3-MA and ACA. Data were represented as mean percentage of cells with GFP-LC3-II punctate ± SD of three independent
experiments. *** p < 0.001 statistically different in comparison to untreated. ### p < 0.001 statistically different in comparison to 3-MA. (D)
Effect of 3-MA on LC3-I/LC3-II protein expression after pre-treatment of 3-MA prior to ACA treatment in A549 and SK-LU-1 cell lines. Data
were represented as normalized intensity ± SD of three independent experiments. * p < 0.05, ** p < 0.01 and *** p < 0.001 statistically
different in comparison to untreated. ## p < 0.01 and ### p < 0.001 statistically different in comparison to 3-MA. (E) Effect of 3-MA on the cell
viability of ACA-treated A549 and SK-LU-1 cell lines. Data represented as mean percentage of cell viability ± SD for three independent
experiments. * p < 0.05 and *** p < 0.001 statistically different in comparison to untreated.
doi:10.1371/journal.pone.0171329.g003
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but dependent on Vps34 and Atg5; verifying Beclin-1-independence [27]. Earlier study also pro-
vided evidence on existence of Beclin-1-independent autophagy induced by resveratrol in human
breast cancer cells when 3-MA was unable to suppress autophagy [28]. It was reported autophagy
activated by proteasome inhibitors and arsenic trioxide is concomitant with reduction in Beclin-
1 expression in ovarian carcinoma cells; suggesting a Beclin-1-independent pathway [29, 30].
These studies provided evidences on the existence of non-canonical autophagy. In the current
study, we found that autophagy induced by ACA was independent of Beclin-1/PI3K complex
which was reflected in the down regulation of Beclin-1. Furthermore, 3-MA, a PI3K inhibitor
was unable to block ACA-induced autophagy and did not potentiate the cytotoxic effect of ACA.
An earlier report has identified NF-κB p65/Rel A as a positive regulator of Beclin-1 expression
[31]. Since ACA was found to inhibit p65/Rel A previously [14], it is possible that the reduction
of Beclin-1 observed upon ACA treatment in this study was as a result of the low expression of
p65/Rel A. However, the underlying mechanism for formation of autophagosome which bypass
the Beclin-1/PI3K complex and the specific function of the non-canonical autophagy in cancer
remains to be further investigated.
Autophagy is a double-edged sword that plays a significant role in tumourigenesis and can-
cer therapeutics. Hence, anti-cancer agents that modulate autophagy may have an important
implication in clinical application. Anti-cancer agents have been found to induce pro-survival
autophagy which eventually contributes to the chemoresistance in NSCLC. Innate resistance
to erlotinib in NSCLC with wild-type epidermal growth factor receptor (EGFR) was as a result
of autophagy [32]. Likewise, gefitinib which is initially effective for inducing death in NSCLC,
was seen to develop resistance due to the pro-survival autophagy [33]. Morover, a recent find-
ing published by Wang et al. indicated knock down of LC3 uing siRNA has a significant impact
on the cell viability of cancerous cells; suggesting LC3 plays an important role in controlling
the cell death [34]. These implied that targeting genes responsible for autophagy can be a strat-
egy for treating chemoresistance that resulted from protective autophagy. In the current study,
we observed that the ACA-induced apoptosis was enhanced in A549 and SK-LU-1 cells when
LC3 was silenced. It reflected that autophagy induced by ACA in NSCLC is limiting the apo-
ptotic cell death.
Studies have shown that gefitinib- and erlotinib-resistance in NSCLC can be resolved by
combine therapy with CQ [32, 33]. For instance, Zou and coworkers reported that CQ has no
growth inhibitory effect on NSCLC even in prolong erlotinib treatment. It also potentiated the
anti-cancer effect of erlotinib [32]. Our present study demonstrated combination of CQ with
ACA exhibited a synergistic anti-cancer effect of ACA as shown in the MTT assay and annexin
V/PI apoptosis assay. Currently, autophagy inhibitors such as CQ and hydroxychloroquine
(HCQ) are under investigation in clinical phase I/II for various cancers including lung cancer
[17, 35]. Results from phase I study had provided a strong evidence that HCQ with or without
erlotinib does not elicit adverse side effects in advance NSCLC patients [36]. Although
Fig 4. Knockdown of LC3 enhanced ACA-induced cytotoxicity through apoptosis. (A) Knockdown efficiency of the three unique 27 mer
siRNA duplexes targeting LC3 in A549 and SK-LU-1. Data were represented as mean percentage of relative intensity ±SD of three independent
experiments. * p < 0.05 and *** p < 0.001 statistically different in comparison to negative control (NC). (B) Effect of siLC3 on ACA-induced
LC3-I/LC3-II protein expression in A549 and SK-LU-1 cell lines. Data were represented as normalized intensity ±SD of three independent
experiments. *** p < 0.001 statistically different in comparison to negative control (NC). (C) Effect of siLC3 on the cell viability of ACA-treated
A549 and SK-LU-1 cell lines. Data represented as mean percentage of cell viability ±SD for three independent experiments. ** p < 0.01 and
*** p < 0.001 statistically different in comparison to negative control (NC). # p < 0.05 and ### p < 0.001 statistically different in comparison to
NC + ACA. (D) Effect of siLC3 on ACA-induced apoptotic cells in A549 and SK-LU-1 cell lines. Representative annexin V-FITC/PI scatter
plots of 1 × 104 cells after 24 h of treatment. Data represented as mean percentage of apoptotic cells ±SD for three independent experiments.
* p < 0.05, ** p < 0.01 and *** p < 0.001 statistically different in comparison to negative control (NC). ### p < 0.001 statistically different in
comparison to NC + ACA.
doi:10.1371/journal.pone.0171329.g004
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available data showed the autophagy inhibitors in combination with anti-cancer agents have
been recognised as a potential strategy to improve the efficiency of the available therapeutic
agents and avoid acquired resistance; the role of autophagy requires further elucidation in
other cancer types due to the fact that the autophagy stimulated by a single compound could
have different role in different cancer types at different stage of cancer development [35].
Conclusion
Collectively, our current study demonstrated for the first time that ACA induced autophagy is
through Beclin-1-independent/non-canonical pathway in NSCLC. In addition, we showed
autophagy inhibitor CQ or inhibition of autophagy gentically by knockdown of LC3 using
siRNA promoted ACA-induced cell death through the apoptosis mechanism. These knowl-
edge suggested targeting autophagy mechanism in cancer therapy may be a promising
approach to sensitized NSCLC to ACA treatment.
Supporting information
S1 Fig. Photomicrograph of A549 and SK-LU-1 upon ACA treatment. (A) Representative
fluorescence photomicrograph (400 × magnification) illustrating the acidic vesicular organ-
elles in A549 and SK-LU-1 cell lines after treatment with ACA. Arrow indicates the acidic
vesicular organelles. (B) Representative fluorescence photomicrograph (400 × magnification)
illustrating the GFP-LC3-II punctate formation in A549 and SK-LU-1 cell lines after ACA
treatment. Arrow indicates the GFP-LC3-II punctate.
(TIF)
S2 Fig. Photomicrograph of A549 and SK-LU-1 after treatment with ACA in presence or
absence of 3-MA. (A) Cells were treated with 3-MA in presence or absence of ACA. Arrow indi-
cates the cytoplasmic vacuole. (B) Representative fluorescence photomicrograph (400 × magnifi-
cation) illustrating the acidic vesicular organelles in A549 and SK-LU-1 cell lines after treatment
with ACA in presence or absence of 3-MA. Arrow indicates the acidic vesicular organelles. (C)
Representative fluorescence photomicrograph (400 × magnification) illustrating the GFP-LC3-II
punctate formation in A549 and SK-LU-1 cell lines upon exposure to co-treatment of 3-MA and
ACA. Arrow indicates the GFP-LC3-II punctate.
(TIF)
Fig 5. Autophagy inhibitor chloroquine enhanced ACA-induced cytotoxicity through apoptosis. (A) Representative fluorescence
photomicrograph (400 ×magnification) illustrating the acidic vesicular organelles in A549 and SK-LU-1 cell lines after treatment with ACA in
presence or absence of CQ. Data were presented as relative fluorescence intensity in comparison to untreated cells ±SD of three independent
experiments. ** p < 0.01 and *** p < 0.001 statistically different in comparison to untreated. # p < 0.05 statistically different in comparison to
CQ. (B) Representative fluorescence photomicrograph (400 ×magnification) illustrating the GFP-LC3-II punctate formation in A549 and SK-LU-
1 cell lines upon exposure to co-treatment of CQ and ACA. Data were represented as mean percentage of cells with GFP-LC3-II punctate ±SD
of three independent experiments. *** p < 0.001 statistically different in comparison to untreated. # p < 0.05 and ### p < 0.001 statistically
different in comparison to CQ. (C) Effect of CQ on LC3-I/LC3-II protein expression after pre-treated with CQ prior ACA treatment in A549
and SK-LU-1 cell lines. Data were represented as normalized intensity ± SD of three independent experiments. * p < 0.05, ** p < 0.01 and
*** p < 0.001 statistically different in comparison to untreated. # p < 0.05 and ## p < 0.01 statistically different in comparison to CQ. (D)
Effect of CQ on the cell viability of ACA-treated A549 and SK-LU-1 cell lines. Data represented as mean percentage of cell viability ± SD for
three independent experiments. *** p < 0.001 statistically different in comparison to untreated. ### p < 0.001 statistically different in
comparison to ACA. (E) Effect of CQ on ACA-induced apoptotic cells in A549 and SK-LU-1 cell lines. Representative annexin V-FITC/PI
scatter plots of 1 × 104 cells after 24 h of treatment. Data represented as mean percentage of apoptotic cells ± SD for three independent
experiments. *** p < 0.001 statistically different in comparison to untreated. # p < 0.05 and ### p < 0.001 statistically different in compari-
son to ACA.
doi:10.1371/journal.pone.0171329.g005
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S3 Fig. Photomicrograph of A549 and SK-LU-1 after treatment with ACA in presence or
absence of CQ. (A) Cells were treated with CQ in presence or absence of ACA. Arrow indicates
the cytoplasmic vacuole. (B) Representative fluorescence photomicrograph (400 ×magnification)
illustrating the acidic vesicular organelles in A549 and SK-LU-1 cell lines after treatment with
ACA in presence or absence of CQ. Arrow indicates the acidic vesicular organelles. (C) Repre-
sentative fluorescence photomicrograph (400 × magnification) illustrating the GFP-LC3-II
punctate formation in A549 and SK-LU-1 cell lines upon exposure to co-treatment of CQ and
ACA. Arrow indicates the GFP-LC3-II punctate.
(TIF)
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